Effect of Transcatheter Arterial Chemoembolization Combined with Argon-Helium Cryosurgery System on the Changes of NK Cells and T Cell Subsets in Peripheral Blood of Hepatocellular Carcinoma Patients.
Hepatocellular carcinoma (HCC) is one of the most aggressive tumors in humans. T lymphocytes and natural killer (NK) cells are the body's first line of defense to prevent tumor cell growth. Previous studies have demonstrated that transcatheter arterial chemoembolization (TACE) combined with argon-helium cryosurgery system (AHCS) can effectively treat liver cancer. However, the mechanism of the treatment is unclear yet. In the current study, we investigated the effects of TACE combined with AHCS on the changes of T cell subsets and NK cells in peripheral blood of HCC. Our data show that alpha-fetoprotein (AFP) levels in peripheral blood were significantly up-regulated in HCC patients before treatment when compared with healthy people and reduced after TACE combined with AHCS treatment (P < 0.01). In addition, we found that CD4+ cells and NK cells decreased (P < 0.05) and CD8+ cells increased (P < 0.05) in HCC patients when compared with healthy people. After treatment, the CD4+ cells, CD4+/CD8+ ratio, and NK cells were dramatically increased in HCC patients (P < 0.05). In contrast, CD8+ cells were significantly decreased (P < 0.05). TACE combined with AHCS treatment significantly prolonged 1-year survival rate of HCC patients and did not show significant side effects. Taken together, our data indicate that TACE combined with AHCS treatment improves patients' immune system. It is a feasible and effective therapeutic method for HCC patients.
Radiology Department, Changsha, China.
Manping
M
Huang
Radiology Department, Changsha, China. wangxiaoyi2014@sina.com.
Xiaoyi
X
Wang
Radiology Department, Changsha, China.
Huang
H
Bin
D000328:Adult; D000368:Aged; D001128:Argon; D016516:CD4-CD8 Ratio; D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000601:surgery / Q000628:therapy; D016022:Case-Control Studies; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D003452:Cryosurgery / Q000009:adverse effects*; D005260:Female; D006371:Helium; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D008113:Liver Neoplasms / Q000276:immunology* / Q000601:surgery / Q000628:therapy; D008297:Male; D008875:Middle Aged
D006371:Helium; D001128:Argon
AHCS; Hepatocellular carcinoma; NK cells; Peripheral blood; T cells; TACE